A Roadmap to Meet 2022 Deadlines, Upcoming Webinar Hosted by Xtalks


Now more than ever, in vitro diagnostic (IVD) manufacturers will need to prepare for the upcoming changes to the clinical and regulatory landscape.

Between the COVID-19 pandemic and BREXIT negotiations, the rapidly approaching deadlines to comply with the new In Vitro Diagnostics Regulation (IVDR) may have a profound impact on market access to products and, ultimately, patient outcomes. Now more than ever, in vitro diagnostic (IVD) manufacturers will need to prepare for the upcoming changes to the clinical and regulatory landscape.

Understanding current guidance and adapted regulations is the first step to navigating transformations that the diagnostics and broader healthcare industries are undergoing.

Join this webinar to learn about today’s IVD regulatory landscape and discuss how manufacturers can develop strategies to ensure a successful transition to comply with the IVDR by the 2022 deadline.

Join Ashleigh Dawley, RAC, Manager, Regulatory Affairs, Regulatory, Reimbursement and Market Access from ICON plc, in a live webinar on Thursday, December 17, 2020 at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit The IVDR Journey: A Roadmap to Meet 2022 Deadlines.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Leave a Reply